Oruka Therapeutics, Inc. (ORKA)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 43/100 (MEDIUM), 220.4 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 15.24% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says
- What Oruka Therapeutics (ORKA)'s Phase 2a Psoriasis Data Means For Shareholders
- Oruka Therapeutics Shares Fall 5% After Week 28 ORKA-001 Trial Data
- Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
- Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
- Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
- H.C. Wainwright Keeps Buy Rating on Oruka (ORKA) After Apogee Acquisition News
- Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Oruka Therapeutics, Inc..
Full ORKA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.